OR WAIT null SECS
The parties are partnering up to leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
Moderna and Thermo Fisher have entered into a 15-year strategic collaboration agreement for the dedicated, large-scale manufacturing of Spikevax, Moderna’s COVID-19 vaccine, in the US. The agreement also applies to other investigational mRNA therapeutic candidates in Moderna’s pipeline.
The contract development and manufacturing organization (CDMO) has been partners with Moderna over the past several years to support Moderna’s development pipeline with both clinical research and contract manufacturing services. The partnership included the quick scale-up of aseptic fill-finish services and packaging of Moderna’s COVID-19 vaccine.
As part of the current, expanded agreement, Thermo Fisher will now provide dedicated capacity for a range of aseptic fill-finish services. These services include lyophilized and liquid filling. Furthermore, the CDMO will provide inspection labeling, and final packaging services.
"Moderna’s innovation in mRNA technology has been pivotal in the global response to the pandemic, and we are proud and privileged to support Moderna over the [p]ast decade,” says Michel Lagarde, executive vice-president and COO of Thermo Fisher Scientific. “In expanding our strategic partnership, Moderna will further leverage our scale and depth of capabilities to continue to transform its mRNA platform and bring new breakthrough medicines to patients around the world."